Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRT + Iparomlimab + Tuvonralimab + SOX as neoadjuvant therapy for gastric/gastroesophageal junction adenocarcinoma
ChiCTR2500108226Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Aug 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Shandong First Medical University. Primary endpoint: Investigator-Assessed Pathological Complete Response Rate (pCR, including primary tumor and lymph nodes). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabtegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500108226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108226.